Document is current

Article History

Received: 16 February 2026

Accepted: 3 April 2026

First Online: 24 April 2026

Declarations

:

: This study was approved by the IUCPQ’s Research ethics committee (CER 2026–4484).

: All patients have provided consent to the present publication.

: The authors declare no competing interests. KG declares the following: Consultancy/Advisory Board for Astra Zeneca, Covis, GlaxoSmithKline, Roche, Sanofi, TEVA, Valeo; Speaker Honoraria for Astra Zeneca, Boehringer, Covis, GlaxoSmithKline, Novartis, Valeo; Funded Grants or Clinical Trials by Astra Zeneca, Bellus, GlaxoSmithKline, Regeneron, Roche, Sanofi, Valeo, Viatris. AC declares the following: Consultancy/Advisory Board for Astra Zeneca, GlaxoSmithKline, Sanofi, Regeneron; Speaker Honoraria for Astra Zeneca, GlaxoSmithKline, Sanofi, Regeneron; Funded Grants or Clinical Trials by Astra Zeneca, GlaxoSmithKline.